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ABSTRACT 
Schizophrenia is a severe mental disorder manifested by positive, negative 
and cognitive symptoms. Current antipsychotic drugs have poor effects on 
negative and cognitive symptoms, thus necessitating the development of new 
antipsychotic treatments. 
 
Dopaminergic stabilizers constitute a novel concept for the treatment of 
schizophrenia. These drugs are claimed to normalize dopaminergic 
transmission in case of either excessive or deficient signalling. Possibly, such 
drugs are particularly useful for treating conditions involving both increased 
and decreased dopaminergic tone, as may be the case in schizophrenia. The 
present thesis focuses on the dopaminergic stabilizers (-)-OSU6162 and 
ACR16. 
 
The main objectives of this thesis were to 1) test the effects of (-)-OSU6162 
and ACR16 in a rat model for negative symptoms, 2) explore their stabilizer 
properties and 3) shed light on the mechanisms of action of these drugs. (-)-
OSU6162 and ACR16 were found to reverse social withdrawal in rats, 
induced by the NMDA receptor antagonist (+)-MK-801. These results 
suggest that these drugs may be effective against negative symptoms of 
schizophrenia. (-)-OSU6162 and ACR16 both had baseline dependent effects 
on motor activity in drug naïve rats, inhibiting behaviour in rats with a high 
motor activity level and stimulating behaviour in rats with a low activity 
level. These effects may be interpreted as support for dopaminergic 
stabilization.  
 
Based on the effects on prolactin secretion observed in the present work and 
results from studies performed in other laboratories, it appears that (-)-
OSU6162, and probably also ACR16, have negligible intrinsic activities at 
the D2 receptor. Thus, the behavioural inhibition caused by these drugs is 
probably a result of D2 receptor blockade. The present results suggest that    
(-)-OSU6162 and ACR16 act via at least two D2-receptor associated targets 
with opposing actions on dopaminergic transmission. A recent in vitro study 
suggests that (-)-OSU6162, apart from blocking the orthosteric site, also 
facilitates receptor activation by binding to an allosteric site at the D2 
receptor. This finding provides a candidate for the activating target for (-)-
OSU6162 and ACR16. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Schizofreni är en allvarlig psykisk sjukdom som kan medföra stort lidande 
för den som drabbas och för hans eller hennes närstående. Symptomen vid 
schizofreni brukar delas in i kategorierna positiva, negativa och kognitiva 
symptom. Positiva symptom syftar på egenskaper som tillförs 
normaltillståndet och omfattar bland annat hallucinationer och 
vanföreställningar. Negativa symptom innebär att förmågor har gått 
förlorade. Bland dessa symptom återfinns isolering från socialt umgänge, 
utslätat känsloliv, viljelöshet och oförmåga att känna njutning. Kognitiva 
symptom medför problem med bland annat uppmärksamhet, minne och 
inlärning. De läkemedel som finns idag för behandling av schizofreni har i 
regel god effekt på positiva symptom. Dessvärre är effekterna på negativa 
och kognitiva symptom inte tillfredsställande. Många av dessa läkemedel är 
dessutom behäftade med allvarliga biverkningar. Därför är det viktigt med 
forskning som syftar till att finna nya, bättre läkemedel mot schizofreni. 
 
Gemensamt för alla nuvarande läkemedel mot schizofreni är att de hämmar 
hjärnans signalering med signalsubstansen dopamin. Detta ledde en gång till 
slutsatsen att signaleringen med dopamin är överaktiv i hjärnan hos personer 
med schizofreni. Det har visat sig att den bilden av dopaminets roll vid 
schizofreni är kraftigt förenklad. Nu tror man istället att signaleringen med 
dopamin kan vara förhöjd i vissa delar av hjärnan och sänkt i andra. Därför är 
en generell hämning av denna signalering troligen inte en optimal strategi vid 
behandling av schizofreni. Vissa av dagens läkemedel kan till och med 
förvärra de symptom som har satts i samband med sänkt signalering med 
dopamin. En annan föreslagen orsak till schizofreni är en felaktig signalering 
med signalsubstansen glutamat. Denna teori baseras på att droger som 
blockerar glutamat-signalering orsakar ett tillstånd hos människa som är 
nästan omöjligt att särskilja från schizofreni. En sådan drog är fencyklidin 
(angel dust), som har varit föremål för omfattande missbruk i framför allt 
USA. 
 
Så kallade dopaminerga stabiliserare är en typ av läkemedel under utveckling 
som kan motverka både förhöjd och sänkt signalering med dopamin i 
hjärnan. Sådana läkemedel skulle kunna vara speciellt användbara vid 
schizofreni som har satts i samband med en kombination av överaktivitet och 
underaktivitet i signaleringen med dopamin. Den här avhandlingen fokuserar 
på de två dopaminerga stabiliserarna OSU6162 och ACR16. 
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Minskat socialt beteende hos råttor som behandlats med vissa droger anses 
motsvara negativa symptom vid schizofreni. Den här avhandlingen visar att 
både OSU6162 och ACR16 kan återställa socialt beteende till normala nivåer 
hos dessa råttor. Detta tyder på att OSU6162 och ACR16 kan vara effektiva 
mot negativa symptom. 
 
Droger som stimulerar signalering med dopamin gör råttor mer aktiva, medan 
droger som hämmar signalering minskar deras aktivitet. Även utan 
behandling med droger varierar signaleringen med dopamin i olika 
situationer och över dygnet, vilket avspeglas i råttornas aktivitet. Det här 
arbetet visar att OSU6162 och ACR16 kan öka aktiviteten hos inaktiva råttor, 
och dessutom minska aktiviteten hos råttor som är aktiva. Det kan tolkas som 
att OSU6162 och ACR16 kan öka signaleringen med dopamin när den är låg 
och hämma signaleringen när den är hög. Således tycks OSU6162 och 
ACR16 verka som dopaminerga stabiliserare.  
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INTRODUCTION 
Schizophrenia 
Schizophrenia is a severe, often life-long, mental disorder which causes 
considerable suffering for those affected and a great cost for society. There 
are three main groups of symptoms associated with schizophrenia, i.e. 
positive, negative and cognitive symptoms. Positive symptoms are traits 
added to normality and comprise hallucinations and delusions. The negative 
and cognitive symptoms both involve loss of function. Negative symptoms 
include social withdrawal, flattened affect, apathy and anhedonia. Cognitive 
symptoms involve impairments in learning, memory, attention and executive 
functions. It should be mentioned in this context that schizophrenia is a very 
heterogeneous condition; there are great variations among schizophrenics 
with respect to the relative severity of different symptoms. This makes it 
necessary to question the concept of schizophrenia as being one single 
disease. The lifetime prevalence of schizophrenia is approximately 1% and 
does not vary across sexes, nationalities, cultures or ethnic groups. 
Schizophrenia is usually said to appear in late adolescence or early 
adulthood, commonly later among women compared to men. This presumed 
age of onset refers to the first psychotic episode. However, this is now 
believed to be preceded by a long prodromal stage of negative and cognitive 
symptoms (Cannon et al., 2002; Carpenter, 2006; Gross, 1997; Mueser and 
McGurk, 2004). 
Pathophysiology of schizophrenic symptoms 
The aetiology of schizophrenia remains unclear. As mentioned above, 
schizophrenia is a heterogeneous condition which points to a heterogeneity in 
both aetiology and pathophysiology (Cardno and Farmer, 1995; Tamminga 
and Holcomb, 2005). As to the pathophysiology, schizophrenic symptoms 
have been put in connection with dysfunctional transmission with a variety of 
different neurotransmitters, e.g. dopamine, glutamate, serotonin, GABA and 
acetylcholine (e.g. Davis et al., 1991; Tamminga, 2006). In this thesis, focus 
is on dopaminergic and glutamatergic transmission which are those most 
commonly discussed in the context of schizophrenia. 
The dopamine hypothesis 
All antipsychotic drugs on the market inhibit dopaminergic signalling to 
some degree, and the effects of antipsychotic drugs on positive symptoms 
often correlate with affinity for dopaminergic D2 receptors (D2Rs). 
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Furthermore, prolonged administration with dopaminergic agonists, such as 
amphetamines and L-DOPA, may cause psychotic symptoms resembling 
positive symptoms of schizophrenia (Angrist et al., 1974b; Srisurapanont et 
al., 2003; Young and Scoville, 1938). In individuals suffering from 
schizophrenia, or with mental illness in the family, one single administration 
of a low dose of amphetamine may be sufficient to temporarily cause or 
worsen psychotic symptoms (Janowsky et al., 1973; Weiner, 1964). Also, 
these psychotic symptoms, resulting from dopaminergic stimulation, may be 
antagonized by antipsychotic drugs (Angrist et al., 1974a; Jha and Fourie, 
1999; Misra and Kofoed, 1997; Misra et al., 2000). Early on, such 
observations led to the dopamine hypothesis of schizophrenia, postulating 
that schizophrenia is due to excessive subcortical dopaminergic activity 
(Randrup, 1970; Snyder, 1973). However, negative and cognitive symptoms 
are not, to any greater extent, induced by dopaminergic agonists or reversed 
by dopaminergic antagonists. Thus, the dopamine hypothesis, in its original 
form, does not provide any plausible mechanism for negative and cognitive 
symptoms. 
 
Instead, drugs stimulating dopamine release are reported to alleviate negative 
symptoms in schizophrenic patients (Benkert et al., 1995; Van Kammen and 
Boronow, 1988). In healthy volunteers, improved working memory has been 
observed in response to a mixed dopaminergic D1/D2 receptor agonist, but 
not after administration of a selective D2R agonist (Müller et al., 1998). 
Furthermore, in subhuman primates it has been demonstrated that low doses 
of D1 receptor (D1R) agonists improve cognitive functions, and that D1R 
antagonists cause worsening of cognitive function. Therefore, a defective 
dopaminergic input to the prefrontal cortex has been suggested as a cause for 
negative and cognitive symptoms. It has also been shown however, that 
excessive D1R stimulation is associated with impaired cognitive 
performance. D1Rs are by far more abundant than D2Rs in the prefrontal 
cortex, and are reported to be up-regulated in schizophrenic patients. This, 
along with the effects of D1R agonists and antagonists, has led to the 
proposal that cognitive deficits, and possibly also negative symptoms, may be 
due to a low D1R stimulation in the prefrontal cortex (Abi-Dargham, 2003; 
Abi-Dargham, 2004; Abi-Dargham and Moore, 2003; Davis et al., 1991). 
Thus, it seems that striatal hyperdopaminergia and cortical hypodopaminergia 
could underlie positive and deficit symptoms respectively. 
 
Investigations indicate that inhibition and stimulation of cortical 
dopaminergic activity induces opposite effects on dopamine levels in the 
striatum, possibly via glutamatergic and GABA-ergic pathways. This 
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suggests that subcortical hyperdopaminergia, resulting in positive symptoms, 
could be at least in part secondary to cortical hypodopaminergia (Abi-
Dargham, 2004; Davis et al., 1991; Tzschentke, 2001). It is interesting in this 
context that negative symptoms and cognitive deficits may exist years before 
the appearance of positive symptoms (Cannon et al., 2002; Gross, 1997). 
The glutamate hypothesis 
N-methyl-D-aspartate receptor (NMDAR) antagonists, such as phencyclidine 
(PCP) and ketamine, are known to induce a state in healthy humans 
practically indistinguishable from schizophrenia. This state includes positive, 
negative as well as cognitive symptoms. In schizophrenic patients these drugs 
may cause relapse or worsening of the symptoms characteristic of the 
patient’s individual psychosis (Krystal et al., 1994; Lahti et al., 2001; Luby et 
al., 1959; Snyder, 1980; Stone et al., 2007). These observations form the 
basis of the glutamate hypothesis of schizophrenia, stating that schizophrenic 
symptoms are a result of dysfunctional glutamatergic signalling. It has been 
suggested that this could be due to malfunctioning NMDARs (Stone et al., 
2007). In support of the glutamate hypothesis are the observed favourable 
effects of some drugs promoting NMDAR function. Such drugs, added to 
antipsychotic treatment, are reported to alleviate negative symptoms and, to 
some degree, cognitive symptoms (Stip and Trudeau, 2005; Tuominen et al., 
2005). It is conceivable that any effect on positive symptoms is masked by 
the patients’ treatment with conventional drugs. In children NMDAR 
antagonists are reported not to cause psychotic symptoms. It seems that 
susceptibility to the psychotomimetic effects of these drugs appear at an age 
when schizophrenia typically would appear. Thus, schizophrenic illness and 
psychotic symptoms caused by NMDAR antagonists could share the same 
mechanisms (Stone et al., 2007). 
Synthesis of the dopamine and glutamate hypotheses 
The dopamine and glutamate hypotheses for schizophrenia are by no means 
incompatible. NMDAR antagonists affect dopamine release both in the 
prefrontal cortex and in the striatum. In rats, repeated administrations 
stimulate dopaminergic transmission in the striatum while transmission is 
decreased in cortex. Thus, a prolonged NMDAR hypofunction could result in 
the dopaminergic aberrations seen in schizophrenia. However, acute 
NMDAR antagonist administration has also been reported to increase cortical 
dopaminergic transmission (Bubser et al., 1992; Jentsch and Roth, 1999). As 
mentioned above, elevated and reduced dopaminergic activity in the 
prefrontal cortex may induce opposite effect in the striatum. This regulation 
of striatal dopaminergic activity is believed to be mediated by glutamatergic 
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pathways, as these have a central role in cortico-striatal signalling (Carlsson 
et al., 1999; Laruelle et al., 2003). Thus, both glutamatergic and 
dopaminergic signalling are undoubtedly altered in schizophrenia. It is 
uncertain which or if one of these phenomena is downstream to the other. 
Antipsychotic treatments 
Comments on intrinsic activity at D2-receptors 
Antipsychotic drugs were until recently characterized as D2R antagonists, i.e. 
without intrinsic activity at D2Rs. The terms “intrinsic activity” and agonism 
are often used synonymously, as if suggesting that all drugs could be 
characterized as either agonists or antagonists. All known dopaminergic 
receptors (D1-D5) are G-protein coupled receptors (GPCRs). According to 
one current simplified model for GPCR function, these receptors are in 
equilibrium between one active and one inactive state. Any ligand that, upon 
binding, may shift this equilibrium has intrinsic activity at the receptor; 
agonists and inverse agonists shift the equilibrium in favour of the active and 
inactive state respectively. This shift is suggested to reflect the ligand’s 
relative preference for either state of the receptor. An active ligand acts 
towards a new equilibrium that reflects its intrinsic activity. An antagonist 
has no preference for any of the two states of the receptor, and does not affect 
the equilibrium in absence of other ligands (Strange, 1999). One could 
conceptualize the intrinsic activities of GPCR ligands as forming a 
continuum ranging from full inverse agonism to full agonism. According to 
this model, the probability of a pure antagonist should be infinitely small 
(Milligan, 2003; Milligan et al., 1995). It is conceivable that the constitutive 
activity of a receptor is not constant and could be partly dependent on the 
circumstances. If so, the effects of drugs would depend, not only on intrinsic 
activity and presence of other ligands, but also on factors determining the 
equilibrium of the receptor. This could be a mechanism involved in 
sensitization/desensitization of receptors. A shift in a receptors constitutive 
activity would not affect the response to a true antagonist. Lately it has been 
shown that a majority of typical and atypical antipsychotic drugs may be, not 
antagonists, but reverse agonists at D2Rs (Akam and Strange, 2004; Hall and 
Strange, 1997; Nilsson et al., 1996; Roberts and Strange, 2005). 
Current antipsychotic medications 
Antipsychotic drugs are often categorized into typical and atypical 
antipsychotics. These two groups of drugs differ mainly with respect to their 
propensity to cause extrapyramidal side effects (EPS). The typical drugs are 
generally laden with serious EPS, whereas atypical drugs have the advantage 
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of causing less EPS. These adverse effects are known to occur at D2R 
occupancies of approximately 80% or higher. It has been suggested that 
atypical drugs are clinically effective at D2R occupancies below that level. 
Another suggested mechanism underlying atypicality is a relatively high 
affinity for serotonergic 5-HT2 receptors versus D2Rs (Kapur and Mamo, 
2003). Yet another suggested advantage of atypical compared to typical drugs 
is a lower propensity to cause mental side effects, i.e. effects similar to the 
negative symptoms of schizophrenia (Lublin et al., 2005; Tandon and Jibson, 
2002). Some atypical drugs do however cause other severe adverse effects 
such as weight gain, increased risk for diabetes and, in the case of clozapine, 
risk of agranulocytosis (Shirzadi and Ghaemi, 2006; Wahlbeck et al., 2000). 
 
Typical and atypical antipsychotic drugs are generally described as equally 
effective for the treatment of positive symptoms. The typical drugs have little 
or no effect on negative or cognitive symptoms, whereas atypical 
antipsychotics are often claimed to be more effective (Stip, 2000). It has been 
pointed out that head to head comparisons of atypical versus typical agents 
may be deceptive, due to the mental side effects of typical antipsychotics. A 
lower propensity for atypical drugs to cause mental side effects could be 
mistaken for an improvement of negative symptoms (Lublin et al., 2005). 
The Cochrane reviews on the subject collectively suggest that, among the 
atypical antipsychotics, only clozapine has a better overall efficacy than 
typical agents (Duggan et al., 2005; El-Sayeh and Morganti, 2006; Hunter et 
al., 2003; Lewis et al., 2005; Srisurapanont et al., 2004; Wahlbeck et al., 
2000). However, the effect of clozapine on primary negative symptoms, i.e. 
not secondary to positive symptoms or antipsychotic treatment, has been the 
subject for animated debate (Carpenter et al., 1995; Carpenter et al., 1996; 
Meltzer, 1995). One would expect that any antipsychotic drug with 
convincing effects on negative symptoms and cognitive deficits would by 
now have received recognition. Thus, the search is on for novel effective 
treatments for this aspect of schizophrenia. 
Dopaminergic stabilizers 
Conceptually, dopaminergic stabilizers are drugs that normalize 
dopaminergic signalling in case of either excessive or deficient dopaminergic 
tone. Such drugs have been proven useful in the treatment of conditions 
involving dysfunctional dopaminergic signalling, e.g. schizophrenia, 
Parkinson’s disease and Huntington’s disease (Gefvert et al., 2000; Petrie et 
al., 1997; Pirtosek et al., 1996; Tamminga and Carlsson, 2002; Tedroff et al., 
1999). Stabilizing of dopaminergic transmission would be particularly useful 
in the treatment of conditions involving both increased and decreased 
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signalling as is suggested in the case of schizophrenia. Also these drugs 
would counteract hyperdopaminergia with little risk of adverse effects 
resulting from excessive dopaminergic inhibition. The few drugs which are 
ascribed dopamine stabilizing effects have been classified as either partial 
D2R agonists or D2R antagonists. This thesis focuses on the latter of these 
two groups. 
 
Aripiprazole (Figure 1) is the only claimed dopaminergic stabilizer having 
reached the market, and is characterized as an atypical antipsychotic agent. 
Thus, it is not laden with any serious EPS. Like most atypical antipsychotic 
drugs, aripiprazole has been described as equal to typical drugs with respect 
to effects on positive symptoms. Individual clinical studies report of 
reductions of negative and cognitive symptoms (Kane et al., 2002; Potkin et 
al., 2003). In a recent meta-study, however, aripiprazole does not appear to 
outdo typical agents in this respect (El-Sayeh and Morganti, 2006). 
Aripiprazole is a partial D2R agonist with low intrinsic activity (Fujikawa et 
al., 1996; Kikuchi et al., 1995). (-)-3-PPP (Figure 1) is another D2R partial 
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Figure 1. Chemical structures 
of dopamine and the claimed 
dopaminergic stabilizers (-)-
OSU6162, ACR16, (-)-3-PPP 
and aripiprazole. 
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agonist also discussed in connection with dopaminergic stabilizers (Carlsson 
et al., 2004). A D2R partial agonist is per definition stabilizing on D2R-
mediated transmission at the level of the receptor; it acts towards a level of 
receptor activation which corresponds to the drug’s intrinsic activity. Thus, in 
case of a low dopaminergic tone, i.e. with a large proportion of receptors at 
rest, the overall effect will be receptor stimulation. In contrast, in case of a 
high dopaminergic tone when a large proportion of D2Rs are in the active 
state, the partial agonist will compete with dopamine and cause an average 
shift in favour of the inactive state, i.e. acting as an antagonist. 
 
The second group of dopaminergic stabilizers comprise two drugs, (-)-
OSU6162 (OSU6162) and ACR16 (Figure 1), which are both structurally 
similar to the above mentioned partial D2R agonists (-)-3-PPP. When these 
drugs were first characterized they were shown to reverse amphetamine-
induced locomotor activation in rats, and to cause behavioural stimulation in 
untreated rats. Thus, it was suggested that they could inhibit or stimulate 
dopaminergic transmission, depending on dopaminergic tone (unpublished 
data, Dept. of Pharmacology, Göteborg University, summary graph published 
in Carlsson, 2001; Sonesson et al., 1994). Small clinical studies with 
OSU6162 suggest antipsychotic effects with respect to both positive and 
negative symptoms (Gefvert et al., 2000; Tamminga and Carlsson, 2002; O. 
Gefvert personal communication). When tested in healthy volunteers, 
OSU6162 was reported to be safe for clinical use (Rodriguez et al., 2004). 
OSU6162 and ACR16 have been described as D2R antagonists (Carlsson et 
al., 2004; Sonesson et al., 1994). An early investigation report of a minor 
affinity of OSU6162 for D2Rs, measured as antagonist and agonist 
displacement in vitro (compound no. 16, Sonesson et al., 1994). Lately, 
however, both OSU6162 and ACR16 were reported to reach D2R 
occupancies of up to 90 % in vivo, measured as raclopride displacement 
(Ekesbo et al., 1999; Natesan et al., 2006). In contrast to the partial agonists, 
there is no obvious mechanism by which D2R antagonists could stabilize 
dopaminergic transmission. One suggested mechanism was a relative 
preference for extrasynaptic versus synaptic D2Rs. It was suggested that, in 
case of low to normal dopaminergic tone, OSU6162 and ACR16 may 
stimulate dopaminergic signalling by blockade of D2 autoreceptors. This 
hypothesis also postulated that, in case of an elevated dopaminergic tone, 
these drugs may dampen transmission mediated extrasynaptic D2 
heteroreceptors (Carlsson et al., 2004). One important objective of this thesis 
was to further study the dopamine stabilizing effects of OSU6162 and 
ACR16, and to evaluate different conceivable mechanisms by which these 
compounds may stabilize dopaminergic neurotransmission. 
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Animal models for schizophrenia 
Another objective of this thesis was to test OSU6162 and ACR16 in an 
experimental model for negative symptoms of schizophrenia. Animal models 
for schizophrenia are indispensable tools for evaluating potential 
antipsychotic drugs. These models mostly involve studies of drug induced 
behaviours believed to correspond to schizophrenic symptoms. The value of a 
model is determined by its predictive validity, i.e. its power to truthfully 
predict different responses in schizophrenic patients. Promising antipsychotic 
drugs should restore behaviour in these animals and validation of a model 
may be accomplished by testing antipsychotic drugs with known properties. 
This is complicated by the lack of antipsychotics alleviating negative and 
cognitive symptoms. Therefore, we must partly rely on face validity, i.e. 
resemblance to symptoms of schizophrenia. 
The amphetamine model 
As discussed above, positive symptoms of schizophrenia may be mimicked 
by administration of dopaminergic agonists, and are also alleviated by D2R 
antagonists. Amphetamine is an indirect dopaminergic agonist, augmenting 
transmission by inducing catecholamine release and preventing 
catecholamine reuptake. Although the effect of amphetamine is not specific 
for dopamine, the abovementioned observations provide evidence that 
dopaminergic mechanisms underlie amphetamine psychosis. Amphetamine is 
used in animal studies to model aspects of schizophrenia. In light of the 
known effects of amphetamine in humans, the flaws of this model are 
obvious. Amphetamine psychosis does not mimic the negative or cognitive 
symptoms of schizophrenia, and hence does not serve to detect effects of 
potential antipsychotic drugs with respect to these symptoms. 
The PCP model 
In humans, administration of the NMDAR antagonists PCP and ketamine 
faithfully mimic most aspects of schizophrenia. This is one observation 
underlying the glutamate hypothesis of schizophrenia, suggesting a defective 
glutamatergic transmission possibly involving dysfunctional NMDARs. 
Consequently, NMDAR antagonists are widely used to model schizophrenia 
in animals. PCP, ketamine and the hitherto not mentioned drug (+)-MK-801 
(MK-801) are non-competitive and use-dependent NMDAR antagonists, 
binding within and obstructing the ion channel of the receptor. Among these 
NMDAR antagonists, MK-801 is by far the most potent (Javitt and Zukin, 
1991). As NMDAR antagonists truthfully mimic most symptoms of 
schizophrenia, these drugs may be expected to provide an animal model with 
superior face validity. 
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Modelling schizophrenic symptoms 
The different symptoms of schizophrenia are believed to correspond with 
different drug-induced behavioural aberrations in rodents. One major 
objective of this thesis was to set up a model for negative symptoms, in order 
to test potential antipsychotics for effect on these symptoms. Social 
withdrawal is regarded a core negative symptom of schizophrenia. 
Measurements of social interactions in animals are relatively easy. Other 
negative symptoms, such as flattened affect or apathy, are difficult or 
virtually impossible to imitate in animals. Unsuccessful attempts have been 
made to model anhedonia by measuring reward seeking behaviours. Animals 
treated with an NMDAR antagonist display marked social withdrawal. Thus, 
inhibition of social interaction, induced by NMDA-receptor antagonists, is 
considered a model for negative symptoms (Ellenbroek and Cools, 2000). 
The model for negative symptoms used in the current work consists of a test 
modified from Sams-Dodd (1995a), and measures social interactions in MK-
801 treated rats. 
 
Locomotor hyperactivity, in response to psychotomimetic drugs, is the most 
commonly used behavioural model for positive symptoms (van den Buuse et 
al., 2005). Hyperactivity induced by amphetamine or NMDAR antagonists is 
reversed by antipsychotic drugs. This indicates both predictive validity and 
dopaminergic involvement in NMDAR antagonist effects. However, it has 
been shown that the NMDAR antagonist MK-801 can induce behavioural 
activation in dopamine depleted mice, indicating that NMDAR antagonist 
induced hyperactivity is partly dopamine independent (Carlsson and 
Carlsson, 1989). It should also be mentioned in this context that atypical 
drugs, with higher degree of serotonergic 5-HT2A receptor antagonism, are 
more effective in antagonizing PCP-induced hyperactivity (Maurel-Remy et 
al., 1995). Cognitive deficits may also be modelled in animals, e.g. with 
different memory tasks (Castner et al., 2004). These will not be discussed in 
this thesis.  
In vivo assessment of D2 receptor effects 
In an attempt to shed light on the mechanisms of action of OSU6162 and 
ACR16, different in vivo models were used to study the D2R effects of these 
drugs. 
Dopaminergic tone measured as motor activity 
There is an undisputed link between dopamine and behavioural activity. 
Enhancement of dopaminergic transmission, with amphetamine or D2R 
agonists, leads to stimulation of motor activity in rodents. Consequently, 
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dopaminergic inhibition such as D2R blockade leads to reduced motor 
activity. Studies indicate a correlation between diurnal variations in motor 
activity and dopamine release in the nucleus accumbens and the dorsal 
striatum (O'Neill and Fillenz, 1985). It has been shown that motor activation 
in a novel environment is associated increased dopamine release in the 
nucleus accumbens (Rebec, 1998). Thus, motor activity may be used as an 
indirect measure of dopaminergic tone. 
Behavioural model for detecting D2 autoreceptor preference 
As mentioned above, preference for extrasynaptic D2Rs is one suggested 
mechanism for dopaminergic stabilization of OSU6162 and ACR16. D2 
autoreceptors are believed to be strictly extrasynaptic and thus exposed to 
much lower dopamine concentrations compared to synaptic receptors. In 
consequence of low dopaminergic stimulation, these receptors are both 
hyper-responsive and available for low concentrations of other ligands. In 
rats, low doses of D2R agonists such as apomorphine cause marked 
locomotor inhibition. This is considered an effect of a reduced dopamine 
release, mediated by D2 autoreceptor stimulation. Reversal of this effect is 
used to detect D2 autoreceptor blockade (Perrault et al., 1997; Ståhle and 
Ungerstedt, 1986). 
Intrinsic activity at D2 receptors in vivo 
Secretion of prolactin from the pituitary gland is regulated largely via D2Rs. 
Thus prolactin release may be used to estimate a drug’s intrinsic activity at 
D2Rs in vivo. In rats, systemic administration of D2R antagonists causes 
marked increase in blood prolactin. Hence, hyperprolactinaemia is a frequent 
side effect of antipsychotic treatment. Conversely, D2R agonists inhibit 
prolactin secretion. In order to facilitate detection of partial agonism, it is 
advisable to minimize the dopaminergic influence on D2Rs on the lactotropic 
cells in the anterior pituitary. This may be achieved by treatment with e.g. 
reserpine or γ-butyrolactone (GBL) (e.g. Carlsson et al., 1986; Inoue et al., 
1996). 
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AIMS OF THE THESIS 
 
The objectives during the course of this work were: 
 
? To set up a rat model for negative symptoms of schizophrenia, based on 
NMDAR antagonist-induced social withdrawal in rats. 
 
? To test the dopaminergic stabilizers OSU6162 and ACR16 in this model 
for possible effects on negative symptoms of schizophrenia. 
 
? To study base-line dependent effects of OSU6162 and ACR16 on motor 
activity in rats, to find indirect support for dopamine stabilizing effects of 
these drugs. 
 
? To shed light on the role of D2 receptors in the mechanism of action of 
OSU6162 and ACR16. 
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METHODS 
Animals 
All experiments were performed with male Sprague Dawley rats weighing 
approximately 250-350 g. All experiments were approved by the animal 
ethics committee in Göteborg, Sweden. 
Behavioural studies 
The video tracking setting 
An automatic video tracking system was used to measure behavioural effects 
of various drug treatments, in rats studied in large rectangular arenas (100 × 
150 cm). The rats were released in the arenas and their movements were 
recorded to videotapes or digital video files using either a colour video 
camera or a video camera sensitive to infrared light. The recordings were 
then analysed using a commercially available video tracking software, 
resulting in tracks describing the animals’ movements in the arenas. 
Behavioural variables were then extracted from these tracks. 
The social interaction test 
Rats were studied in pairs in the video tracking setting. In order to capture 
behaviour during the active hours of the rats’ diurnal rhythm, the rats were 
housed in reverse daylight cycle. The arenas were illuminated with ultraviolet 
light and the rats were marked with fluorescent dyes of different colours. This 
enabled the tracking software to identify the rats without risking interfering 
too much with the rats’ light-dependent activity level. The two rats were 
injected simultaneously with an identical combination of MK-801 and test 
drug. 30 minutes after injection the two rats were introduced into the same 
arena and filmed for 30 minutes. Social behaviour was measured as percent 
of the observation time spent in proximity to each other. One “in proximity” 
period started when the rats came within 20 cm of each other, and ended as 
the distance between the rats exceeded 25 cm. The rats’ motor activity was 
also measured as mean velocity. In this model, each pair of rats was treated 
as one object in the statistical analysis. Therefore mean values were 
calculated for in each pair in an experiment. 
Motor activity of active rats 
These rats were housed in reverse daylight cycle and motor activity was 
measured for individual rats in the video tracking system. In these 
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experiments the arenas were illuminated with infrared light. Under these 
conditions the arenas appear to be in compete darkness. The test drug was 
injected and 30 minutes later one rat was released into each arena. Behaviour 
was studied for 30 minutes and motor activity was measured as mean 
velocity. 
Apomorphine-induced hypomotility 
Motor activity was measured in infrared light as described above. 
Apomorphine and test drugs were injected 5 minutes and 30 minutes 
respectively prior to recording of behaviour. 
Motor activity of inactive rats 
Rats used for these experiments were housed in normal daylight cycle. Motor 
activity was measured in small illuminated activity boxes (40 × 40 cm) with 
5×5 rows of infrared beams at floor level. A computer connected to the 
activity boxes registered activity measured as unrepeated beam breaks, i.e. 
two or several consecutive breakings of one beam were counted as one beam 
break. The rats were allowed to habituate for 65 minutes to the boxes, and 
were then injected with test drugs. The rats were returned to the boxes and 
motor activity was measured for 60 minutes. 
Drug effects on prolactin in vivo 
Test drugs were injected and 60 minutes later the rats were decapitated and 
trunk blood was collected. Blood samples were centrifuged and plasma 
prolactin levels were assessed using a commercially available enzyme 
immunoassay kit specific for rat prolactin. 
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RESULTS 
The social interaction test 
The NMDA-receptor antagonist MK-801 induced a substantial and dose-
dependent inhibition of social interactions in rats (figure 2). MK-801 also 
caused stimulation of motor activity. Amphetamine caused marked 
stimulation of motor activity and appeared to have a weak tendency to 
stimulate social interactions. These data combined with later observations 
suggest that there is no relation between these two behavioural variables. 
 
OSU6162 and ACR16 both reversed MK-801-induced social withdrawal 
(figure 3). This effect was accompanied by inhibition of motor activity. In 
previously untreated rats neither OSU6162 nor ACR16 had any significant 
effects on social interactions, but induced marked inhibition of motor 
activity. Preliminary data indicate that also aripiprazole reverses MK-801-
induced social withdrawal and hyperactivity. 
 
Haloperidol dose-dependently added to the social withdrawal induced by 
MK-801. It also caused a marked inhibition of motor activity. At the highest 
dose tested the rats’ activity was negligible. Clozapine did not induce any 
statistically significant effects on social interactions or motor activity when 
added to MK-801. It did, however, have a statistically significant effect on a 
third variable measured in these experiments, i.e. time in inner zone. All 
drugs tested in the social interaction setting, except amphetamine, caused the 
rats to spend less time in a predefined inner zone of the arena. 
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Figure 3. The effects of (a) (-)-OSU6162 and (b) ACR16 on (+)-MK-801 (0.2 mg/kg) 
induced social withdrawal measured as proximity. Comparisons are made versus the 
(+)-MK-801 treated group using ANOVA followed by Dunnett’s post hoc test. * p<0.5. 
Data previously presented in paper II. 
Baseline-dependent effects on motor activity 
Rats housed in reversed daylight cycle and studied in large unlit arenas 
without any prior habituation to the environment had a high initial activity 
level. Motor activity dropped markedly, but did not level out during the 30 
minutes of observation. OSU6162 and ACR16 induced marked inhibition of 
activity. ACR16 caused a steeper decline in activity, than did OSU6162 
(figure 4). Haloperidol, aripiprazole and (-)-3-PPP induced considerable 
behavioural inhibition of the same magnitude as OSU6162 and ACR16, 
whereas amisulpride inhibited motor activity only at a very high dose. 
 
Motor activity was also measured in small illuminated activity boxes. The 
rats were housed in normal daylight cycle and allowed to habituate to the 
boxes before the drug was administered. The rats were fully habituated to the 
boxes at the time of drug injection, in the sense that motor activity was 
minimal. Apart from a transient activation that resulted from the injection, the 
control rats remained almost completely inactive. These rats responded to 
OSU6162 and ACR16 with a distinct behavioural activation (figure 5). This 
effect was not seen in response to haloperidol, aripiprazole, (-)-3-PPP or 
amisulpride. 
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Figure 4. Effects of (a) (-)-OSU6162 and (b) ACR16 on motor activity of active rats. 
Activity was measured as velocity in the video tracking setting. Statistical comparisons 
were made versus control with univariate general linear model, followed by Dunnet’s 
post hoc test. ** p<0.01; *** p<0.001 (i.p. injections). ### p<0.001 (s.c. injections). 
Graphs extracted from paper III. 
Apomorphine-induced hypomotility 
Apomorphine induced a biphasic inhibitory effect on motor activity. The 
maximal behavioural inhibition was seen at the dose 0.16 µmol/kg (0.05 
mg/kg), which was also used subsequently in these studies. 
 
OSU6162 induced a modest but statistically significant reversal of 
apomorphine induced hypomotility (figure 6a). ACR16 did not affect motor 
activity in rats treated with this dose of apomorphine. With a lower dose of 
apomorphine (0.08 µmol/kg), however, treatment with ACR16 tended to add 
to the apomorphine-induced behavioural inhibition. Amisulpride (figure 6b) 
restored motor activity of apomorphine-treated rats to a level approaching 
that of controls. Haloperidol did not have any distinct effect in this model. 
Effects on prolactin release 
OSU6162 (figure 7a) and haloperidol (figure 7c) induced similar dose-
dependent increases of prolactin secretion. ACR16 also stimulated prolactin 
secretion dose-dependently, but to a lesser extent (figure 7b). Within a 
reasonable dose-interval, the effect of ACR16 on prolactin release was 
modest compared to that of OSU6162 and haloperidol. Aripiprazole induced 
increased prolactin release of a magnitude similar to that of ACR16 (figure 
7d). 
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DISCUSSION 
The social interaction test 
As mentioned in the Introduction, social withdrawal is one negative symptom 
of schizophrenia with a measurable counterpart in animal behaviour. Thus, 
social withdrawal in rats is considered a model for negative symptoms. Paper 
I describes a setting for automated measurements of social interactions in 
rats. This setting is similar to one described previously by Sams-Dodd 
(1995a). 
Face validity 
Paper I reports of social withdrawal and locomotor stimulation in rats in 
response to acute administration of MK-801. Similar results had previously 
been reported in rats after acute or subchronic treatment with MK-801, PCP 
or ketamine (e.g. Becker and Grecksch, 2004; Sams-Dodd, 1994; Sams-
Dodd, 1995b; Sams-Dodd, 1996; Silvestre et al., 1997). PCP and ketamine 
both cause a schizophrenia-like state in humans which includes negative 
symptoms. These are observations that contributed to the glutamate 
hypothesis and the PCP-model of schizophrenia. 
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Figure 5. Effects of (a) OSU6162 and (b) ACR16 on motor activity of habituated rats 
in activity boxes during t=0-30 minutes and t=30-60 minutes after injection. 
Statistically significant effects were established with Kruskal-Wallis one-way analysis 
of variance by ranks, and comparisons versus control were performed as described 
by Siegel and Castellan (1988). * p<0.05; ** p<0.01; *** p<0.001 (t=0-30 min).   
# p<0.05, ## p<0.01, ### p<0.001 (t=30-60 min). Graphs extracted from paper III. 
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Figure 6. Effects of (a) (-)-OSU6162 and (b) amisulpride on apomorphine induced 
hypomotility in rats. Apomorphine (0.16 µmol/kg) and test drugs were administered 5 
and 30 minutes respectively prior to registration. Motor activity was measured for 30 
minutes as velocity in the video tracking setting. Statistical comparisons were made 
versus the apomorphine group with univariate general linear model, followed by 
Dunnet’s post hoc test. * p<0.05; *** p<0.001. Graphs extracted from paper III. 
In contrast to the PCP-model, the amphetamine model is not believed to 
cover the negative symptoms of schizophrenia. In our investigation, rats 
responded to acute administration of amphetamine with a weak tendency 
towards increased social interactions. This result agrees with earlier work 
showing an equivalent response at similar doses (Sams-Dodd, 1995b). In 
summary, NMDAR antagonists cause marked social withdrawal in rats while 
amphetamine has only minor effects on social behaviour. Thus, considering 
the schizophrenia-like effects of NMDAR antagonists, social withdrawal in 
response to NMDAR antagonists provides a model for negative symptoms 
with face validity. 
 
Predictive validity 
In paper II haloperidol caused a marked decrease in social interactions when 
added to MK-801, whereas clozapine was without effect. Subchronic 
administration of some atypical drugs is reported to partly reverse social 
withdrawal in rats treated subchronically with PCP. These results have been 
considered as supportive of the predictive validity of this model for negative 
symptoms. However, with the possible exception of sertindole, these drugs 
had only marginal effects on social withdrawal and/or they had significant 
effects in previously untreated rats (Sams-Dodd, 1997). Furthermore, most 
researchers in the field now seem to question that atypical antipsychotics 
have advantages over typical agents with respect to effects on negative 
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.
symptoms. Thus, there are currently no drugs that could establish the 
predictive validity of this model. 
Effects of dopaminergic stabilizers 
In paper II the dopaminergic stabilizers OSU6162 and ACR16 were 
compared with the typical antipsychotic drug haloperidol and the atypical 
agent clozapine with respect to effects on MK-801-induced social 
withdrawal. As mentioned above, haloperidol caused further inhibition of 
social interactions whereas clozapine was without effect. In contrast, 
OSU6162 and ACR16 both restored social interactions to a level similar to 
that of controls. When tested in drug naïve rats these drugs did not have any 
significant effects on social interactions. This indicates that the dopaminergic 
stabilizers OSU6162 and ACR16 specifically blocked MK-801-induced 
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Figure 7. The effects of (a) (-)-OSU6162 (b) ACR16 (c) haloperidol and (d) aripiprazole 
on prolactin secretion in drug naïve rats. Treatment groups were compared to control 
group with univariate general model, followed by the Dunnet’s post hoc test. * p<0.05;   
** p<0.01; *** p<0.001. Graphs extracted from paper IV
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social withdrawal. Unpublished data indicate that aripiprazole too may 
restore social interactions in this setting. In a recent study aripiprazole was 
found to reverse PCP-induced social withdrawal in rats (Bruins Slot et al., 
2005). Thus, these results indicate that the dopaminergic stabilizers 
OSU6162, ACR16 and aripiprazole could provide effective treatment for 
negative symptoms. As mentioned in the Introduction, OSU6162 has 
produced promising results in small studies with schizophrenic patients. 
These clinical studies indicate a rapid onset of antipsychotic effects with 
respect to both positive and negative symptoms. OSU6162 also appeared to 
be effective in patients with treatment resistant schizophrenia (Gefvert et al., 
2000; Gefvert et al, unpublished; Lundberg et al., 2002; Tamminga and 
Carlsson, 2002). Interestingly, patients are reported to become more sociable 
in response to OSU6162 (O. Gefvert, personal communication). 
Dopaminergic stabilization 
Stabilizing effects on motor activity 
In paper III we used two different settings in order to measure drug induced 
effects on spontaneous motor activity in rats with different activity baseline; 
one in which rats were highly active and one in which the behavioural 
activity was minimal. We found that the most important factors affecting 
activity level were habituation to the test equipment and the size of the 
arenas. Based on the convincing evidence for a strong correlation between 
dopaminergic tone and behavioural activity, we made the assumption that 
these differences in arousal reflect differences in dopaminergic activity; the 
active and inactive rats having high and low dopaminergic tone respectively. 
This assumption is supported by preliminary biochemistry data showing that 
active rats, compared to inactive rats, have higher concentrations of 
homovanillic acid in the striatum, indicating a higher dopaminergic activity. 
 
We found that OSU6162 and ACR16 caused marked locomotor inhibition in 
active rats, whereas inactive rats were clearly stimulated by these drugs. The 
inhibition of behaviour in active rats was visible also in the data presented in 
paper II. In other studies OSU6162 and ACR16 were shown to be either 
stimulating or without effect on behavioural activity (Natesan et al., 2006; 
Sonesson et al., 1994). Aripiprazole and (-)-3-PPP caused potent inhibition of 
motor activity in the active rats, and did not induce any activation in the 
inactive rats. As increased and reduced motor activity can indicate 
stimulation and inhibition of dopaminergic signalling respectively, the effects 
of OSU6162 and ACR16 may be interpreted as activity dependent effects on 
dopaminergic signalling. OSU6162 and ACR16 have been shown to reverse 
amphetamine induced hyperactivity in rats, in a setting where these drugs are 
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otherwise stimulating (Natesan et al., 2006). This confirms that OSU6162 
and ACR16 may reverse hyperactivity resulting from a hyperdopaminergic 
state. Thus, these results show that OSU6162 and ACR16 are probable 
dopaminergic stabilizers. Our data do not, however, confirm the stabilizing 
effects of aripiprazole or (-)-3-PPP. 
Partial agonism as a mechanism for dopaminergic stabilization 
A partial agonist is per definition stabilizing on transmission at the level of 
the receptor; it acts towards a level of receptor activation reflecting its 
intrinsic activity, which is below that of a full agonist. The partial D2R 
agonist properties of aripiprazole and (-)-3-PPP have been demonstrated in 
vitro as sub-maximal activation of D2Rs and, at least for aripiprazole, partial 
reversal of receptor activation exerted by full agonists. These studies show 
that aripiprazole’s intrinsic activity is clearly below that of (-)-3-PPP (Cosi et 
al., 2006; Jordan et al., 2007a; Jordan et al., 2007b; Natesan et al., 2007; 
Urban et al., 2007). The direct effects of these drugs at D2Rs have also been 
investigated in vivo. Both (-)-3-PPP and aripiprazole have been reported to 
reverse DOPA-accumulation induced by reserpine or GBL (Ahlenius et al., 
1989; Kikuchi et al., 1995). Aripiprazole has been shown to stimulate 
prolactin secretion in drug naïve rats, and to reverse hyperprolactinaemia 
induced by reserpine (Inoue et al., 1996). In female rats, (-)-3-PPP has been 
shown to stimulate prolactin release, whereas male rats responded with 
decreased prolactin secretion. These results were interpreted as a higher 
sensitivity of D2Rs in the pituitary of male rats, as a result of lower dopamine 
concentrations at these receptors (Carlsson and Eriksson, 1989). In both male 
and female rats, however, (-)-3-PPP have been shown to reverse 
hyperprolactinaemia induced by reserpine or GBL (Carlsson et al., 1986; 
Hjorth et al., 1985). In female rats with GBL-induced hyperprolactinaemia, it 
was also shown that (-)-3-PPP partly reversed suppression of prolactin 
release induced by the its isomer (+)-3-PPP, which has considerably higher 
intrinsic activity (Carlsson et al., 1987). (-)-3-PPP also partly reverses 
haloperidol-induced stimulation on prolactin secretion (Svensson et al., 
1993). Together, these observations confirm the stabilizing effects of 
aripiprazole and (-)-3-PPP at receptor level. 
 
The data presented in paper III indicate that, under physiological conditions, 
the partial D2R agonists aripiprazole and (-)-3-PPP act inhibiting on the 
dopaminergic system regardless of level of arousal. These results agree with 
previously reported dose-dependent locomotor inhibition in response to (-)-3-
PPP (Hjorth et al., 1983). It has been claimed that the D2R agonist effects of 
aripiprazole and (-)-3-PPP are visible as yawning behaviour in drug naïve rats 
(Fujikawa et al., 1996). This interpretation is contradicted by recent work 
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suggesting that D2/D3 agonist induced yawning is mediated by D3 receptors, 
while D2Rs mediate reversal of yawning at high doses of these drugs (Collins 
et al., 2007; Collins et al., 2005). However, after reserpine-induced 
dopamine-depletion, rats respond to (-)-3-PPP with a minor stimulation of 
motoractivity (Hjorth et al., 1983). (-)-3-PPP has also been observed to 
alleviate symptoms in patients with Parkinson’s disease (Pirtosek et al., 1993; 
Pirtosek et al., 1996; Verhagen Metman et al., 1994). In one investigation, 
aripiprazole failed to reverse hypoactivity in mice, induced by a lower dose 
of reserpine (Kikuchi et al., 1995). Thus, aripiprazole and (-)-3-PPP suppress 
dopaminergic transmission under normal circumstances. Also, (-)-3-PPP can 
stimulate dopaminergic neurotransmission in case of arrested dopaminergic 
signalling. This may, however, not be the case for aripiprazole. Furthermore, 
(-)-3-PPP has been observed to diminish the treatment-induced motor 
fluctuations in patients with Parkinson’s disease (Pirtosek et al., 1993). (-)-3-
PPP may thus be considered a dopaminergic stabilizer. Aripiprazole, 
however, seems to be altogether inhibitory on the dopaminergic system, 
albeit stimulating at the receptor level under extraordinary circumstances. 
Nevertheless, aripiprazole has been shown not to cause EPS even at D2R 
occupancies of up to 95% (Gründer et al., 2003). 
 
In this context it is useful to consider the background for using partial D2R 
agonists in the treatment of schizophrenia: Low doses of full D2R agonists 
have been shown to alleviate psychotic symptoms; an effect that fades within 
days of treatment. This antipsychotic effect is attributed to inhibition of 
dopamine synthesis and release via D2 autoreceptors. These receptors are 
believed to be exclusively extrasynaptic and therefore, compared to synaptic 
heteroreceptors, exposed to minimal amounts of dopamine. As a consequence 
of the low dopamine concentration at these receptors, they are available for 
low levels of exogenous ligands and also hypersensitive to D2R agonists. The 
disruption of the antipsychotic effect of D2R agonists is attributed 
desensitization of presynaptic receptors; the antipsychotic effect is known to 
subside more rapidly with higher intrinsic activity of the drug. In the case of 
(-)-3-PPP the antipsychotic effect wore off over the first two weeks of 
treatment. Thus, D2R partial agonists with lower intrinsic activities were 
sought that could achieve suppression of dopamine release, without causing 
desensitization of autoreceptors. Aripiprazole could be such a partial agonist, 
since schizophrenic patients are not reported to develop tolerance to this drug 
(Carlsson and Carlsson, 2006; Tamminga, 2002). 
Mechanism for stabilization by OSU6162 and ACR16 
Lately it has been shown in vitro that OSU6162 has a slight agonist effect at 
D2Rs (Lahti et al., 2007; Seeman and Guan, 2007). This, however, does not 
DISCUSSION 
 
33 
seem to be the case for ACR16; recently published data could be interpreted 
as a minor inverse agonist effect of this drug (Tadori et al., 2007). In paper 
IV it was observed that OSU6162 appears to stimulate prolactin release in 
rats as effectively as haloperidol, which is in agreement with an antagonist 
action of OSU6162 at D2Rs. ACR16 caused a considerably smaller increase 
in prolactin secretion within a reasonable dose interval. In our study, as well 
as in previous studies (Inoue et al., 1996; Natesan et al., 2007), aripiprazole 
caused a modest increase in prolactin release. Thus, it may be suggested that 
the intrinsic activity of OSU6162 is negligible, compared to that of 
aripiprazole. Therefore, the dopaminergic stabilizer properties of OSU6162 
and ACR16 cannot be due to partial D2R agonism. 
 
Furthermore, it has been shown that the activating effect of OSU6162 is lost 
in dopamine depleted rats (Sonesson et al., 1994). Thus, it appears that, in 
contrast to partial D2R agonists, this drug is dependent on dopamine for its 
activating effect. As mentioned in the Introduction, one hypothesized 
mechanism for dopaminergic stabilization of OSU6162 and ACR16 is a 
preference for extrasynaptic D2Rs. In paper III these drugs were tested for 
D2 autoreceptor preference, measured as blockade of apomorphine-induced 
hypomotility. Our results indicate that OSU6162, but not ACR16, has some 
preference for D2 autoreceptors versus synaptic receptors. The same study 
also showed that the autoreceptor preference of OSU6162 was modest 
compared to that of the known autoreceptor preferring drug amisulpride (cf. 
Perrault et al., 1997). According to the abovementioned hypothesis, 
dopaminergic activation of OSU6162 and ACR16 would be due to 
autoreceptor blockade. Therefore, it was expected that amisulpride would 
also induce behavioural stimulation in inactive rats, but this turned out not to 
be the case. Thus, taken together, these results contradict the hypothesis of 
preference for extrasynaptic receptors as the mechanism for dopaminergic 
stabilization of OSU6162 and ACR16.  
 
The behavioural effects presented in paper III shows that OSU6162 is less 
inhibitory on activity compared to ACR16. This is what would be expected if 
OSU6162 were the least potent D2R antagonist of these drugs. However, in 
paper IV OSU6162 was much more effective in stimulating prolactin release, 
indicating that OSU6162 is on the contrary more potent than ACR16. This 
result agrees with a recent in vivo study where OSU6162 was shown to more 
potently than ACR16 displace raclopride in a striatal dopamine D2R 
occupancy experiment (Natesan et al., 2006). Furthermore, OSU6162 was 
also the more activating of the drugs in inactive rats, an effect that cannot be 
attributed to blockade of postsynaptic receptors. These observations indicate 
that at least two different targets are involved in the stabilizing effects of 
OSU6162 and ACR16. The most likely mechanism for inhibition is blockade 
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of postsynaptic D2Rs. As to the activating effect of these drugs, the results in 
paper III indicate that this is not mediated by D2 autoreceptors. However, 
since activation is dependent on the presence of dopamine, the activating 
target should nevertheless be associated with dopaminergic receptors. 
 
Interestingly, in a recent in vitro study, low concentrations of OSU6162 were 
shown to potentiate the effect of dopamine at D2Rs, whereas higher 
concentrations inhibited receptor activation. The interpretation of these data 
was that OSU6162 enhances the effect of dopamine via an allosteric site at 
the D2R, whereas inhibition results from blockade of the dopamine-site of 
the receptor (Lahti et al., 2007). This finding lends support for D2 
heteroreceptor blockade as the mechanism for inhibition of dopaminergic 
signalling and motor activity. More importantly, it offers a strong candidate 
for the activating target of OSU6162 and ACR16. 
Summary 
NMDAR antagonist-induced social withdrawal is a model for negative 
symptoms of schizophrenia with face validity. Since current antipsychotics 
do not appear to have satisfactory effects on these symptoms we do not have 
the means to verify the predictive validity of this model. The dopaminergic 
stabilizers OSU6162 and ACR16 were shown to reverse social withdrawal in 
rats induced by the NMDAR antagonist MK-801. This result suggests that 
these drugs may be effective against negative symptoms of schizophrenia. 
OSU6162 and ACR16 were shown to reduce motor activity in highly active 
drug naïve rats, and to increase activity in inactive previously untreated rats. 
These effects lend support to the dopamine stabilizer properties of these 
drugs. OSU6162 partly reversed apomorphine-induced locomotor inhibition, 
which indicates a relative preference for the extrasynaptic D2 autoreceptors. 
Since ACR16 did not share this property, and since the known D2 
autoreceptor selective drug amisulpride did not induce any behavioural 
activation, these studies contradict preference for extrasynaptic receptors as a 
mechanism for dopaminergic stabilization. Nevertheless, the behavioural 
responses to these drugs suggest that two separate drug targets, both 
associated with dopaminergic receptors, mediate activation and inhibition of 
behaviour. Together with recently published data from another lab, these data 
indicate that inhibition is an effect of orthosteric D2R blockade, whereas the 
activating target could be an allosteric site of the D2R, mediating an 
enhanced response to dopamine. 
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CONCLUSIONS 
 
The studies in this thesis have resulted in the followed main conclusions: 
 
Social interactions 
? MK-801-induced social withdrawal in rats is a model for negative 
symptoms of schizophrenia with face validity 
? The claimed dopaminergic stabilizers OSU6162 and ACR16 reversed 
MK-801-induced social withdrawal, suggesting beneficial effects on 
negative symptoms 
 
Dopaminergic stabilization 
? OSU6162 and ACR16 had base-line dependent effects on motor activity 
in drug naïve rats, which can be interpreted as support of dopaminergic 
stabilization. 
? Dopamine stabilizing effects of aripiprazole and (-)-3-PPP do not show 
up in the present behavioural model with drug naïve rats. 
? The dopamine stabilizing properties of OSU6162 and ACR16 may 
consist of: 
▫ Inhibition by blockade of the orthosteric, i.e. the dopamine binding, 
site of the postsynaptic D2 receptor 
▫ Stimulation via interaction with an allosteric site of the D2 receptor 
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